Immunic (IMUX) to Release Quarterly Earnings on Wednesday

Immunic (NASDAQ:IMUX) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Trading Up 0.7 %

Shares of NASDAQ IMUX traded up $0.01 on Monday, reaching $1.38. 11,291 shares of the company traded hands, compared to its average volume of 785,714. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11. The company has a 50 day moving average of $1.33 and a 200 day moving average of $1.26.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IMUX shares. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, April 27th. Brookline Capital Management reaffirmed a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, April 5th.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.